Table 1. Clinical trials.
| Name | Category | Compounds | Setting | Phase | NCT | Results |
|---|---|---|---|---|---|---|
| ENERGIZE | CPI + Chemo | Nivolumab + chemo +/– IDO1-inhibition | NAC | III | NCT03661320 | No |
| BLASST-1 | CPI + Chemo | Nivolumab + chemo | NAC | II | NCT03294304 | Yes |
| GU14-188 | CPI + Chemo | Pembrolizumab+ chemo | NAC | Ib/II | NCT02365766 | Yes |
| NABUCCO | CPI + CPI | Nivolumab + ipilimumab | NAC | Ib | NCT03387761 | Yes |
| SAKK 06/17 | CPI + Chemo | Durvalumab + chemo | Perioperative | II | NCT03406650 | Yes |
| NIAGARA | CPI + Chemo | Durvalumab + chemo | Perioperative | III | NCT03732677 | No |
| Keynote-866 | CPI + Chemo | Pembrolizumab+ chemo | Perioperative | III | NCT03924856 | No |
| IMvigor 130 | CPI + Chemo | Atezolizumab + chemo | Metastasis, first-line | III | NCT02807636 | Yes |
| CheckMate 901 | CPI+CPI/CPI+ Chemo | Nivolumab + ipilimumab/nivolumab + chemo | Metastasis, first-line | III | NCT03036098 | No |
| DANUBE | CPI + CPI | Durvalumab + ipilimumab | Metastasis, first-line | III | NCT02516241 | Yes |
| NILE | CPI +/– CPI + Chemo | Durvalumab +/– tremelimumab + chemo | Metastasis, first-line | III | NCT03682068 | No |
| Keynote-361 | CPI + Chemo | Pembrolizumab+ chemo | Metastasis, first-line | III | NCT02853305 | Yes |
| PEANUT | CPI + Chemo | Pembrolizumab+ albumin-bound paclitaxel | Metastasis, first-line | II | NCT03464734 | Yes |
| CheckMate 032 | CPI + CPI | Nivolumab + ipilimumab | Metastasis, second-line | I/II | NCT01928394 | Yes |
| FIERCE22 | CPI + FGFR3 | Pembrolizumab+ vofatamab | Metastasis, second-line | Ib/II | NCT03123055 | Yes |
| EV-103 | CPI + Nectin 4-inhibition | Pembrolizumab+ enfortumab-vedotin | Metastasis, first-line | Ib | NCT0328854 | Yes |
| NORSE | CPI + panFGFR | Cetrelimab + erdafitinib | Metastasis, first-line | II | NCT03473743 | Yes |
| EV-302 | CPI + Nectin 4-inhibition +/– Chemo | Pembrolizumab + enfortumab vedotin +/– platinum-based chemotherapy | Metastasis, first-line | III | NCT04223856 | No |
Chemo, chemotherapy; CPI, checkpoint inhibitor; FGFR3, fibroblast growth factor receptor 3.